NCT06185452View on ClinicalTrials.gov

Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine

PHASE4CompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

September 26, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
HIV-1 Infection
Interventions
DRUG

Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration

Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as standard of care.

DRUG

Out of Hospital long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg administration

Out of Hospital administration of long-acting Vocabria (cabotegravir) 600 mg and long-acting Rekambys (rilpivirine) 900 mg as an optional therapy in HIV-Infected patients from Spain.

Trial Locations (9)

29601

Cs Leganitos, Málaga

29603

Hospital Costa Del Sol, Málaga

29692

Cs San Pedro de Alcántara, Málaga

Cs San Luis de Sabinillas, San Luis de Sabinillas

08916

Germans Trias I Pujol Hospital, Badalona

08001

CAP Dr ROBERT, Barcelona

Centre de Salut Internacional i Malalties Transmissibles Drassanes - Vall d'Hebron, Barcelona

08015

BCN CheckPoint, Barcelona

08035

Hospital Vall D' Hebrón, Barcelona

All Listed Sponsors
lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT06185452 - Implementation of Out-of-HOspital Administration of the Long-Acting Cabotegravir+Rilpivirine | Biotech Hunter | Biotech Hunter